- Home
- DLHC vs SRZN Comparison
DLHC vs SRZN Comparison
Compare DLHC & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- SRZN
- Stock Information
- Founded
- DLHC 1969
- SRZN 2015
- Country
- DLHC United States
- SRZN United States
- Employees
- DLHC N/A
- SRZN N/A
- Industry
- DLHC Business Services
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- DLHC Consumer Discretionary
- SRZN Health Care
- Exchange
- DLHC Nasdaq
- SRZN Nasdaq
- Market Cap
- DLHC 79.6M
- SRZN 85.6M
- IPO Year
- DLHC N/A
- SRZN N/A
- Fundamental
- Price
- DLHC $5.55
- SRZN $10.61
- Analyst Decision
- DLHC
- SRZN Strong Buy
- Analyst Count
- DLHC 0
- SRZN 2
- Target Price
- DLHC N/A
- SRZN $38.50
- AVG Volume (30 Days)
- DLHC 29.0K
- SRZN 12.4K
- Earning Date
- DLHC 08-06-2025
- SRZN 08-08-2025
- Dividend Yield
- DLHC N/A
- SRZN N/A
- EPS Growth
- DLHC 80.25
- SRZN N/A
- EPS
- DLHC 0.31
- SRZN N/A
- Revenue
- DLHC $359,723,000.00
- SRZN $12,621,000.00
- Revenue This Year
- DLHC N/A
- SRZN N/A
- Revenue Next Year
- DLHC N/A
- SRZN N/A
- P/E Ratio
- DLHC $18.05
- SRZN N/A
- Revenue Growth
- DLHC N/A
- SRZN N/A
- 52 Week Low
- DLHC $2.72
- SRZN $5.90
- 52 Week High
- DLHC $11.42
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- DLHC 48.00
- SRZN 61.84
- Support Level
- DLHC $5.43
- SRZN $9.03
- Resistance Level
- DLHC $5.75
- SRZN $10.95
- Average True Range (ATR)
- DLHC 0.18
- SRZN 0.91
- MACD
- DLHC -0.03
- SRZN 0.05
- Stochastic Oscillator
- DLHC 24.49
- SRZN 73.39
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).